AR056800A1 - Uso de inhibidores de la pde iii para el tratamiento de la isuficiencia cardiaca asintomatica ( oculta ) - Google Patents
Uso de inhibidores de la pde iii para el tratamiento de la isuficiencia cardiaca asintomatica ( oculta )Info
- Publication number
- AR056800A1 AR056800A1 ARP060104928A ARP060104928A AR056800A1 AR 056800 A1 AR056800 A1 AR 056800A1 AR P060104928 A ARP060104928 A AR P060104928A AR P060104928 A ARP060104928 A AR P060104928A AR 056800 A1 AR056800 A1 AR 056800A1
- Authority
- AR
- Argentina
- Prior art keywords
- hidden
- isufficiency
- asydomatic
- cardiac
- treatment
- Prior art date
Links
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 title abstract 2
- 230000000747 cardiac effect Effects 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000001235 sensitizing effect Effects 0.000 abstract 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 229960002105 amrinone Drugs 0.000 abstract 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 abstract 1
- 229960000692 levosimendan Drugs 0.000 abstract 1
- 229960003574 milrinone Drugs 0.000 abstract 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002164 pimobendan Drugs 0.000 abstract 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05110689 | 2005-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056800A1 true AR056800A1 (es) | 2007-10-24 |
Family
ID=37744668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104928A AR056800A1 (es) | 2005-11-14 | 2006-11-10 | Uso de inhibidores de la pde iii para el tratamiento de la isuficiencia cardiaca asintomatica ( oculta ) |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20070112010A1 (https=) |
| EP (2) | EP3210605A1 (https=) |
| JP (1) | JP5312034B2 (https=) |
| CN (2) | CN102784394A (https=) |
| AR (1) | AR056800A1 (https=) |
| AU (1) | AU2006310997B2 (https=) |
| CA (1) | CA2629367C (https=) |
| DK (1) | DK1951227T3 (https=) |
| ES (1) | ES2631879T3 (https=) |
| HU (1) | HUE033546T2 (https=) |
| PL (1) | PL1951227T3 (https=) |
| TW (1) | TW200735874A (https=) |
| WO (1) | WO2007054514A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| FI20040674A0 (fi) | 2004-05-12 | 2004-05-12 | Orion Corp | Menetelmä tromboembolisten sairauksien estoon |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| EP2279009A4 (en) * | 2008-05-05 | 2011-09-21 | Univ Rochester | METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE |
| CN102223882B (zh) | 2008-11-25 | 2016-02-03 | 贝林格尔.英格海姆维特梅迪卡有限公司 | 用于治疗肥厚型心肌病的III 型磷酸二酯酶(PPE III)抑制剂或Ca2+敏化剂 |
| NL1037569C2 (en) * | 2009-12-18 | 2011-06-21 | Eurovet Animal Health B V | Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use. |
| EP3167876B1 (en) * | 2012-03-15 | 2021-09-08 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| EP3021832B9 (en) | 2013-07-19 | 2023-03-15 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| CA2930033C (en) | 2013-12-04 | 2022-12-13 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
| US10537570B2 (en) * | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| EA039250B1 (ru) * | 2016-06-01 | 2021-12-23 | Бёрингер Ингельхайм Ветмедика Гмбх | Применение пимобендана для уменьшения размера сердца и замедления начала клинических симптомов у пациентов с асимптоматической сердечной недостаточностью вследствие митрального порока сердца |
| WO2022073954A1 (en) | 2020-10-08 | 2022-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan in the anaesthesia of non-human mammals |
| TW202508593A (zh) | 2023-05-24 | 2025-03-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES482789A0 (es) | 1978-08-25 | 1980-12-01 | Thomae Gmbh Dr K | Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona |
| GB8400863D0 (en) * | 1984-01-13 | 1984-02-15 | Smith Kline French Lab | Chemical compounds |
| EP0220044B1 (en) * | 1985-10-17 | 1991-01-30 | Smith Kline & French Laboratories Limited | 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl derivatives |
| US4868182A (en) | 1986-11-05 | 1989-09-19 | Merrell Dow Pharmaceuticals Inc. | Enhancement of prazosin |
| DE3804490A1 (de) * | 1988-02-12 | 1989-08-24 | Heumann Pharma Gmbh & Co | Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| GB8824458D0 (en) | 1988-10-19 | 1988-11-23 | Orion Yhtymae Oy | Substituted pyridazinones |
| GB8903130D0 (en) | 1989-02-11 | 1989-03-30 | Orion Yhtymae Oy | Substituted pyridazinones |
| GB2251615B (en) | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
| WO2003012030A2 (en) * | 2001-08-01 | 2003-02-13 | University Of Utah, Technology Transfer Office | Isoform-selective inhibitors and activators of pde3 cyclic |
| EP1579862A1 (en) * | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
-
2006
- 2006-11-08 HU HUE06829958A patent/HUE033546T2/hu unknown
- 2006-11-08 DK DK06829958.5T patent/DK1951227T3/en active
- 2006-11-08 AU AU2006310997A patent/AU2006310997B2/en active Active
- 2006-11-08 CN CN201210144177XA patent/CN102784394A/zh active Pending
- 2006-11-08 CA CA2629367A patent/CA2629367C/en active Active
- 2006-11-08 JP JP2008540580A patent/JP5312034B2/ja active Active
- 2006-11-08 WO PCT/EP2006/068231 patent/WO2007054514A2/en not_active Ceased
- 2006-11-08 EP EP17165100.3A patent/EP3210605A1/en not_active Withdrawn
- 2006-11-08 ES ES06829958.5T patent/ES2631879T3/es active Active
- 2006-11-08 PL PL06829958T patent/PL1951227T3/pl unknown
- 2006-11-08 CN CNA2006800424125A patent/CN101309685A/zh active Pending
- 2006-11-08 EP EP06829958.5A patent/EP1951227B1/en active Active
- 2006-11-10 AR ARP060104928A patent/AR056800A1/es not_active Application Discontinuation
- 2006-11-13 TW TW095141963A patent/TW200735874A/zh unknown
- 2006-11-14 US US11/559,467 patent/US20070112010A1/en not_active Abandoned
-
2010
- 2010-07-07 US US12/831,657 patent/US20100273807A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL1951227T3 (pl) | 2017-09-29 |
| CN102784394A (zh) | 2012-11-21 |
| JP2009515927A (ja) | 2009-04-16 |
| AU2006310997B2 (en) | 2013-01-10 |
| ES2631879T3 (es) | 2017-09-05 |
| CA2629367A1 (en) | 2007-05-18 |
| DK1951227T3 (en) | 2017-07-10 |
| EP1951227B1 (en) | 2017-04-12 |
| HUE033546T2 (hu) | 2017-12-28 |
| JP5312034B2 (ja) | 2013-10-09 |
| US20100273807A1 (en) | 2010-10-28 |
| CA2629367C (en) | 2016-05-03 |
| US20070112010A1 (en) | 2007-05-17 |
| EP3210605A1 (en) | 2017-08-30 |
| EP1951227A2 (en) | 2008-08-06 |
| TW200735874A (en) | 2007-10-01 |
| CN101309685A (zh) | 2008-11-19 |
| AU2006310997A1 (en) | 2007-05-18 |
| WO2007054514A3 (en) | 2007-09-07 |
| WO2007054514A2 (en) | 2007-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048588A1 (es) | Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca | |
| AR056800A1 (es) | Uso de inhibidores de la pde iii para el tratamiento de la isuficiencia cardiaca asintomatica ( oculta ) | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| BRPI0412343A (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
| NO20060981L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
| UY28958A1 (es) | Nuevos derivados de piridazin-3(2h)-ona | |
| NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
| AR087241A2 (es) | Derivados de 6-oh-4h-benzo[1,4]oxazin-3-ona para el tratamiento de la enfermedad pulmonar obstructiva cronica | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| BRPI0714908B8 (pt) | derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende | |
| TW200626138A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| MA31358B1 (fr) | Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone | |
| NO20071512L (no) | Terapeutiske kombinasjoner omfattende poly(ADP-ribose)polymeraseinhibitor. | |
| UY27890A1 (es) | Tratamiento terapeutico | |
| JP2015536973A (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| MX2009001660A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis. | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| EA200201276A1 (ru) | Производные арилметиламина для использования в качестве ингибиторов триптазы | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| Kassab | Recent advances in targeting COX-2 for cancer therapy: a review | |
| AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| AR081925A1 (es) | Uso de ranolazina para el tratamiento de la hipertension pulmonar | |
| ES2215327T3 (es) | Composicion de medicamento inmunomodulador. | |
| ITMI20042475A1 (it) | Uso di derivati tiazolidinonici come agenti terapeutici | |
| ATE306267T1 (de) | Kombinationsbehandlung bei akutem myokardinfarkt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |